Realizing the full clinical potential of circular and self-amplifying RNAs across infectious diseases, CAR-T therapy, gene therapy and beyond with improved efficacy, functionality and immunogenicity. May 28 – 29, 2025 • Boston, MA
Signals Start of New Commercialization Phase for LineaRx SubsidiaryCompany Negotiating GMP Supply AgreementCompany Reaffirms Strategic Restructuring Timeline STONY BROOK, N.Y., January 10, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) […]
Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, N.Y., December 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic […]
Fast track your mRNA-based vaccines and therapeutics from discovery to commercialization by ensuring targeted delivery, durability and tolerable immunogenicity across all disease indicators. July 21-23, 2025 • Boston, MA
LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the 2025 mRNA Process Development & CMC Summit, September 23 – 25 in Boston, MA.
Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing STONY BROOK, N.Y. September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: LineaRx will present its Linea™ IVT […]
– Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA – STONY BROOK, N.Y., September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity […]
Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, N.Y. – July 29, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 – 31, 2024, in Boston. The poster […]
via use of the Linea IVT Platform | Chemically-Modified, Enzymatically-Produced IVT Templates + a Next-Generation RNA Polymerase Yuhua Sun | Huan Dong | Qiang Zhao | Finly Philip | Clay Shorrock | Aaron Chung | James Hayward Enter information below to download our poster!
Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, N.Y., and JUPITER, FL – June 20, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA […]